GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE291nnn/GSE291053/primaryOK200Methylation profilingHomo sapiensMethylation profiling by genome tiling arrayhttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291053GEOGSEfalseGenome wide DNA methylation analysis in a prospective observational study identifies several epigenetically deregulated genes during renal replacement therapy at ESRD.Renal replacement therapy (RRT) can be initiated in the end-stage renal disease (ESRD). Over four million people worldwide receive RRT. Haemodialysis (HD) is the most frequently employed treatment, followed by peritoneal dialysis (PD), while conservative treatment (CT) is selected more frequently for elderly individuals, particularly women. The molecular mechanisms of ESRD-RRT, and its possible impact on cellular processes, are not yet fully understood, although recent evidence suggests a correlation between epigenetic regulation of chromatin dynamics, mainly DNA methylation, and control of gene transcription in this pathology. This investigation represents the first prospective study of epigenomic alterations during HD, PD and CT treatments in ESRD. Advanced Infinium EPIC array technology, capable of measuring levels of DNA methylation of over 850,000 CpG sites in the genome, was used in peripheral blood mononuclear cells. The results show an inverse relationship between the methylation levels of certain CpGs of significant genes and changes in gene expression during the different ESRD treatments. Namely, the genes FBXWD7, TMEM229B and MZF1 in CT group, NELL1, CBLN1 and EEF1D in HD group and COX11, TMCO and RSPO3 in PD group. These genes are linked to inflammation, oxidative stress, immune response, mitochondrial disorders, pericardial oedema, vascular congestion or metabolic diseases. The findings suggest that these genes may contribute to the differing prognoses observed between the different treatment groups. The epigenomic alterations identified could contribute to the pathophysiology and prognosis of ESRD and may represent important therapeutic targets for the improvement of future treatment options.2026/06/02GSE291053GSM8828079GSM8828078GSM8828077GSM8828099GSM8828098GSM8828097GSM8828096GSM8828095GSM8828094GSM8828093GSM8828092GSM8828091GSM8828090GSM8828105GSM8828104GSM8828103GSM8828102GSM8828101GSM8828100GSM8828089GSM8828088GSM8828087GSM8828086GSM8828085GSM8828084GSM8828083GSM8828082GSM8828081GSM8828080GSM8828108GSM8828107GSM882810621145291053Homo sapiens